NFKB1 and B-cell chronic lymphocytic leukemia: Accordingly, our data show that the exposure of CLL cells to PI3K-inhibiting concentrations of idelalisib reduces the activity of NF-kB and upregulates the nuclear expression levels of FOXO3A in a dose-dependent manner.